XML 65 R22.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
Stockholders' Equity |
14. | Stockholders’ Equity
In connection with the closing of an underwritten public offering on April 12, 2017, the Company issued Series A Preferred Stock. During the year ended December 31, 2018, 3,680 shares of the Series A Preferred Stock were converted into 736,000 shares of common stock of the Company. As of December 31, 2018, there were no shares of Series A Preferred stock issued and outstanding. On February 13, 2018, the Company entered into an underwriting agreement with JonesTrading, in connection with a registered firm commitment underwritten public offering of 2,941,176 shares of common stock, pursuant to a shelf registration statement that was declared effective by the SEC on February 6, 2018. On February 15, 2018 the Company sold 3,382,352 shares of common stock (including 441,176 shares of common stock sold pursuant to the exercise of the underwriters’ overallotment option) at a price to the public of $34.00 per share. The net proceeds to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company were approximately $106.8 million. In connection with the closing of the underwritten public offering on April 12, 2017, the Company also issued warrants to purchase 2,070,000 shares of common stock at an exercise price of $5.50 per share. Upon their issuance, the common stock warrants were determined to be equity instruments under ASC 480 and ASC 815-40. The net proceeds allocated to the warrants based on a relative fair value basis resulted in $5.0 million being allocated to the warrants. As of December 31, 2019, the Company had no warrants outstanding associated with this offering. The following is a summary of warrant activity for the year ended December 31, 2019 and 2018:
|  | Number of Shares |  |  | Weighted Average |
|  | Underlying Warrants |  |  | Exercise Price |
Outstanding — December 31, 2017 |  |  | 1,751,708 |  |  | $ | 6.46 |
Issued |  |  | — |  |  |  |  |
Exercised |  |  | (1,735,419 | ) |  | $ | 5.50 |
Forfeited/Cancelled (1) |  |  | (6,095 | ) |  | $ | 5.50 |
Outstanding — December 31, 2018 |  |  | 10,194 |  |  | $ | 155.73 |
Issued |  |  | — |  |  |  |  |
Exercised |  |  | — |  |  |  |  |
Forfeited/Cancelled |  |  | (2,337 | ) |  | $ | 499.50 |
Outstanding — December 31, 2019 |  |  | 7,857 |  |  | $ | 53.61 |
(1) | In November 2018, 1,845 warrants were cancelled by Healthcare Ventures VIII, a related party.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration